Omega Perficio
Welcome to The Brain Institute of America!
The Institute has been diligently uncovering the molecular underpinnings of cancer by studying non-coding RNAs. Often considered the dark matter of the genome, because so few knew much about the function of these genetic elements, non-coding RNA genes remain an unexplored resource of genetic information that has been linked to a number of diseases within the past decade and could very well explain the nature of a number of central nervous system tumors including glioblastoma multiform.
Glioblastoma multiform and various neurological disorders are debilitating diseases that are also associated with socio-economic hardship and emotional trauma amongst family members and friends caring for that individual.
The Brain Institute of America was formed in 2017 with the goal of developing biomarkers for a variety of neurological disorders and malignancies of the central nervous system. The mission is to develop effective RNA based biomarkers for these disorders. The Brain Institute of America is specifically focused on non-coding RNAs, a type of biomolecule that operates by controlling the abundance of a genetic element. Several noncoding RNAs found to be highly expressed in brain tissue are currently being pursued for biomarker development.
The Brain Institute of America is a biomedical research company operating in New Haven, CT with access to state of the art equipment and facilities. Currently we are in Phase I development which is geared towards developing biomarkers for clinical use. In phase II, curated biomarkers will be commercialized into a product for clinical testing and use.
We thank everyone for their kind support in developing our programs!
Multiple Sclerosis, ‘la sclérose en plaques', is a disease that attacks the myelin sheath of the nervous system; first described by Jean Martin Charcot in 1868. Read more here https://shorturl.at/AKY59 #MultipleSclerosis #news #Science #RNA #Neurology @brainamerica @BrainAmerFndn
Happy Birthday!
